The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Dealing with Simultaneous Cancer & Rheumatic Disease

Dealing with Simultaneous Cancer & Rheumatic Disease

March 17, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Because rheumatic disease therapies tamp down immune responses, the question, Dr. Cappelli said, is, “What happens when the forces of immune activation outweigh those of inhibition? … Unfortunately, with these immune checkpoint inhibitors, there’s no free lunch.”

You Might Also Like
  • Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Explore This Issue
March 2018
Also By This Author
  • Treatment Challenges, Uncertainty Abound with IgA Vasculitis

ICIs can cause a wide array of immune-related adverse events (irAEs), affecting all body systems. Such events can range in severity and in timing, but combination ICI treatment tends to lead to more common events of all types, Dr. Cappelli said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a systematic review published in 2016, the four most common irAEs were found to be inflammatory arthritis, sicca syndrome, polymyalgia rheumatica and giant cell arteritis (PMR/GCA), and myositis.3

A guideline for how to handle inflammatory arthritis that emerges with ICI therapy was published last year. Its authors suggested that in the mildest cases, physicians should continue the immunotherapy, with NSAIDs and consideration of prednisone or intra-articular steroids. For moderate cases, they also suggest continuing immunotherapy at first, but to consider holding it if there’s no response to oral prednisone after at least four weeks. In severe cases, they suggest holding immunotherapy, trying oral prednisone for four weeks, and then considering TNF inhibitors or methotrexate.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Sicca is treated with saliva substitutes, sialogogues, artificial tears and other therapies. In PMR/GCA, Dr. Cappelli said, inflammatory markers are almost always elevated, with corticosteroids the mainstay treatment. And in myositis, ICIs are held or stopped in almost all cases, with cortico­steroids as the standard treatment.

‘What happens when the forces of immune activation outweigh those of inhibition?’ —Dr. Cappelli

Can Immunosuppression Affect Cancer Treatment?

Dr. Cappelli said rheumatologists and oncologists have concerns about giving immunosuppression to treat irAEs.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“[The] first, and I think the foremost, worry is, are we abrogating the anti-tumor effect of the immune checkpoint inhibitors? Are we impairing natural tumor defenses, and are there overlapping side effects?” she said. “Ultimately, it’s a multidisciplinary discussion to decide on treatment because there’s limited data in the published literature.”

Can patients with autoimmune disorders who develop cancer be treated with ICIs? Patients with rheumatic diseases were excluded from the original clinical trials, so there’s not much data to go on, she said.

One case series found eight of 30 melanoma patients with a variety of rheumatic conditions had an exacerbation of the underlying illness, with most managed with steroids but with two inflammatory bowel disease patients needing infliximab. In another case series, 20 of 52 melanoma patients had a flare of their autoimmune condition that required immunosuppression, and two discontinued their ICI because of the flare.

Pages: 1 2 3 | Single Page

Filed Under: Meeting Reports, Scleroderma Tagged With: ACR/ARHP Annual MeetingIssue: March 2018

You Might Also Like:
  • Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • The Latest Data on Cancer Immunotherapy’s Interaction with Autoimmunity

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)